These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 16138637)

  • 21. [Start of insulin therapy. How to ensure patient compliance?].
    MMW Fortschr Med; 2006 Aug; 148(35-36):12-3. PubMed ID: 16995354
    [No Abstract]   [Full Text] [Related]  

  • 22. Glycemic Control in Adult Type 1 Diabetes Patients with Insulin Glargine, Insulin Detemir, or Continuous Subcutaneous Insulin Infusion in Daily Practice.
    Rautiainen P; Tirkkonen H; Laatikainen T
    Diabetes Technol Ther; 2018 May; 20(5):363-369. PubMed ID: 29741925
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective audit of the introduction of insulin glargine (lantus) into clinical practice in type 1 diabetic patients.
    Gallen IW; Carter C
    Diabetes Care; 2003 Dec; 26(12):3352-3. PubMed ID: 14633830
    [No Abstract]   [Full Text] [Related]  

  • 24. [Long acting insulin analogs: possibly more stable glucose regulation].
    Huvers F
    Ned Tijdschr Geneeskd; 2004 Aug; 148(34):1674-8. PubMed ID: 15453119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of AIR inhaled insulin compared to insulin lispro in patients with type 1 diabetes mellitus in a 6-month, randomized, noninferiority trial.
    Comulada AL; Renard E; Nakano M; Rais N; Mao X; Webb DM; Milicevic Z
    Diabetes Technol Ther; 2009 Sep; 11 Suppl 2():S17-25. PubMed ID: 19772445
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine.
    Doyle EA; Weinzimer SA; Steffen AT; Ahern JA; Vincent M; Tamborlane WV
    Diabetes Care; 2004 Jul; 27(7):1554-8. PubMed ID: 15220227
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Flexible intensive insulin therapy: a change in mentalities].
    Penfornis A; Chabroux S; Grimaldi A
    Rev Med Interne; 2008 Nov; 29(11):857-60. PubMed ID: 18387717
    [No Abstract]   [Full Text] [Related]  

  • 28. Glargine versus NPH insulin: efficacy in comparison with insulin aspart in a basal bolus regimen in type 1 diabetes--the glargine and aspart study (GLASS) a randomised cross-over study.
    Chatterjee S; Jarvis-Kay J; Rengarajan T; Lawrence IG; McNally PG; Davies MJ
    Diabetes Res Clin Pract; 2007 Aug; 77(2):215-22. PubMed ID: 17141354
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy.
    Kazda C; Hülstrunk H; Helsberg K; Langer F; Forst T; Hanefeld M
    J Diabetes Complications; 2006; 20(3):145-52. PubMed ID: 16632233
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimization of basal insulin delivery in Type 1 diabetes: a retrospective study on the use of continuous subcutaneous insulin infusion and insulin glargine.
    Fahlén M; Eliasson B; Odén A
    Diabet Med; 2005 Apr; 22(4):382-6. PubMed ID: 15787660
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes.
    Hamann A; Matthaei S; Rosak C; Silvestre L;
    Diabetes Care; 2003 Jun; 26(6):1738-44. PubMed ID: 12766103
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Basal insulin substitution with glargine or continuous subcutaneous insulin infusion in adult type 1 diabetes patients-a randomized controlled trial.
    Bragd J; von Döbeln A; Lins PE; Adamson U; Bergström J; Oskarsson P
    Diabetes Technol Ther; 2010 Sep; 12(9):689-93. PubMed ID: 20687863
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Conversion from intravenous insulin to subcutaneous insulin after cardiovascular surgery: transition to target study.
    Shomali ME; Herr DL; Hill PC; Pehlivanova M; Sharretts JM; Magee MF
    Diabetes Technol Ther; 2011 Feb; 13(2):121-6. PubMed ID: 21284478
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distinct pharmacodynamics of insulin glargine and insulin detemir: crossover comparison in Type 1 and Type 2 diabetic patients on basal-bolus regimen.
    Kato T; Tokubuchi I; Muraishi K; Sato S; Kato T; Hara K; Tanaka K; Kaku H; Tajiri Y; Yamada K
    Diabetes Res Clin Pract; 2010 Dec; 90(3):e64-6. PubMed ID: 20850885
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glycemic control with insulin glargine as part of an ethnically diverse, community-based diabetes management program.
    Philis-Tsimikas A; Zhang Q; Walker C
    Am J Ther; 2006; 13(6):466-72. PubMed ID: 17122525
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus.
    Mullins P; Sharplin P; Yki-Jarvinen H; Riddle MC; Haring HU
    Clin Ther; 2007 Aug; 29(8):1607-19. PubMed ID: 17919543
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ultra-long-acting insulins for a lifestyle-related pandemic.
    Kudva YC; Basu A
    Lancet; 2011 Mar; 377(9769):880-1. PubMed ID: 21396704
    [No Abstract]   [Full Text] [Related]  

  • 38. [Clinical experiences with Levemir treatment].
    Jendle J; Norberg B
    Lakartidningen; 2007 Jan 10-16; 104(1-2):54. PubMed ID: 17323744
    [No Abstract]   [Full Text] [Related]  

  • 39. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes.
    Ashwell SG; Amiel SA; Bilous RW; Dashora U; Heller SR; Hepburn DA; Shutler SD; Stephens JW; Home PD
    Diabet Med; 2006 Mar; 23(3):285-92. PubMed ID: 16492212
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Intensified insulin therapy of type 2 diabetes mellitus: pre- or postprandial injection of aspart insulin?].
    Jungmann E
    Dtsch Med Wochenschr; 2005 May; 130(20):1254-7. PubMed ID: 15889321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.